PAN PACIFIC L Y M P H O M A CONFERENCE20

21SCHEDULE

Monday, Aug 9 — Interprofessional Education

7:00 a.m. Conference Registration / Breakfast

7:45 a.m. WelcomeMatthew A. Lunning, DO, FACPTawny J. Roeder, RN, BSN, BMTCN

8:00 a.m. High Cost Services in Lymphoma Theresa Franco, MSN, RN

8:40 a.m. Involving Palliative Care in Lymphoma Management Meg Trewhitt, APN-BC, AOCNP

9:10 a.m. Recognizing and Treating Depression and Anxiety in Lymphoma PatientsDavid S. Kroll, MD

9:40 a.m. Supportive Therapies for Novel Oral TherapiesSusanne E. Liewer, PharmD, BCOP, FHOPA

10:10 a.m. Refreshment Break

10:25 a.m. Radiographic Images in LymphomaChristin A. Tiegs Heiden, MD

11:05 a.m. Anticoagulation Management in Hematologic Malignancies Krishna Gundabolu, MBBS, FACP

11:35 a.m. Utilization of APPs in Lymphoma: Roundtable Robbe L. Peetz, MMS, PA-C

12:15 p.m. Adjourn

1:00-3:00 p.m. Symposium

3:00-5:00 p.m. Symposium

Tuesday, Aug 10

7:00 a.m. Registration / Breakfast

7:30 a.m. WelcomeJames O. Armitage, MDJulie M. Vose, MD, MBA

What’s Next in LymphomaMODERATOR: Julie M. Vose, MD, MBA

7:40 a.m. What’s Next for PET/CT in Lymphoid MalignanciesSally F. Barrington, MBBS, MSc, FRCP, FRCR, MD

8:05 a.m. What’s Next for Pathologic Assessment in Lymphoid Malignancies Kai Fu, MD, PhD

8:30 a.m. What’s Next for Radiotherapy in Lymphoid Malignancies Charles A. Enke, MD

8:55 a.m. What’s Next for Antibody Drug Conjugates (ADCs) in Lymphoid MalignanciesBrad S. Kahl, MD

9:20 a.m. What’s Next for Bispecific T-cell Engager (BiTE) Antibodies in Lymphoid MalignanciesChristopher R. Flowers, MD, MS, FASCO

9:50 a.m. What’s Next for Non-CD20 Based Monoclonal Antibodies in Lymphoid MalignanciesNancy L. Bartlett, MD

10:05 a.m. Break

Revised 03/11/20

MODERATOR: Richard I. Fisher, MD

10:30 a.m. BEACOPP: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin Lymphoma Andreas Engert, MD

10:55 a.m. ABVD: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin LymphomaAlison J. Moskowitz, MD

11:20 a.m. When to Employ PET in Indolent Non-Hodgkin LymphomaJudith Trotman, MBChB, FRACP, FRCPA

11:45 a.m. Novel Imaging Modalities in Multiple MyelomaChristin A. Tiegs Heiden, MD

12:10 p.m. Novel Combination Therapies in Newly Diagnosed Multiple MyelomaNina Shah, MD

12:35 p.m. Novel Strategies in Relapsed and Refractory Multiple MyelomaMuhamed Baljevic, MD

1:00-3:00 p.m. Symposium

3:00-4:00 p.m. Lymphoma Jeopardy Semifinals Matthew A. Lunning, DO, FACP

Semi’s #1 Semi’s #2TEAM NORTH:Stephen M. Ansell, MD, PhDBrad S. Kahl, MDNancy L. Bartlett, MDSonali M. Smith, MD

TEAM SOUTH:Nathan H. Fowler, MDCraig H. Moskowitz, MDJonathon B. Cohen, MD, MSLoretta J. Nastoupil, MD

TEAM EAST:Jonathan W. Friedberg, MD, MMScJeremy S. Abramson, MDAndrew D. Zelenetz, MD, PhDCarla Casulo, MD

TEAM WEST:Ranjana H. Advani, MDDavid G. Maloney, MD, PhDKerry J. Savage, MD, MSc, FRCPCAlison J. Moskowitz, MD

4:00-5:00 p.m. Ask the Experts: iNHLMODERATOR: Philip J. Bierman, MDJonathon B. Cohen, MD, MS Loretta J. Nastoupil, MDMatthew Davids, MD, MMSc

7:00-9:00 p.m. Welcome Reception

Wednesday, Aug 11

7:00 a.m. Breakfast

Moving CAR-T ForwardMODERATOR: Matthew A. Lunning, DO, FACP

7:30 a.m. Management of CAR-T ToxicitiesDavid G. Maloney, MD, PhD

7:55 a.m. Manipulating the T-cell Before and After Apheresis Jeremy S. Abramson, MD

8:20 a.m. Manipulating the CAR-T Construct Renier J. Brentjens, MD, PhD

8:45 a.m. Is There a Best T-cell Phenotype for CAR-T?David Miklos, MD, PhD

9:10 a.m. CAR-T in ChinaPeihua (Peggy) Lu, MD

9:35 a.m. CAR-T for Other NHLJulie M. Vose, MD, MBA

10:00 a.m. Break

MODERATOR: Julie M. Vose, MD, MBA

10:15 a.m. James O. Armitage Lymphoma Clinical Investigator AwardLoretta J. Nastoupil, MD

11:05 a.m. Oliver Press Memorial LectureHistorical Development of Hodgkin Therapy at Stanford Ranjana H. Advani, MD

11:55 a.m. Lymphoma Jeopardy FinalsMatthew A. Lunning, DO, FACP

12:45 p.m. Adjourn

1:00-3:00 p.m. Symposium

3:00-4:00 p.m. Ask the Experts: HGBCL MODERATOR: James O. Armitage, MDAndrew D. Zelenetz, MD, PhDGrzegorz S. Nowakowski, MDNancy L. Bartlett, MD

4:00-5:00 p.m. Ask the Experts: cHL MODERATOR: R. Gregory Bociek, MD, MSc, FRCP(C)Craig H. Moskowitz, MDAlison J. Moskowitz, MDAndreas Engert, MD

5:00 p.m. Adjourn

Thursday, Aug 12

7:00 a.m. Breakfast

Quick Draw (For or Against)MODERATOR: Matthew A. Lunning, DO, FACP

7:30 a.m. Utilization of a BTK Inhibitor in 1st Line CLL/SLL Alexey V. Danilov, MD, PhDSusan M. O’Brien, MD

8:00 a.m. Integration of Non-CAR-T Based Immunotherapies in the Management of Non- Hodgkin Lymphoma Stephen M. Ansell, MD, PhDBruce D. Cheson, MD, FACP, FAAAS, FASCO

8:30 a.m. Utilization of a Cell Free DNA Assessment in Non-Hodgkin Lymphoma Management  Andrew D. Zelenetz, MD, PhDJeremy S. Abramson, MD

9:00 a.m. Utilization of a Minimal Residual Disease Assessment in Non-Hodgkin Lymphoma Management Matthew Davids, MD, MMScCarla Casulo, MD

9:30 a.m. Utilization of Oral Therapies in First Line Indolent Non-Hodgkin Lymphoma ManagementNathan H. Fowler, MDJonathan W. Friedberg, MD, MMSc

10:00 a.m. Break

MODERATORS: Keely M. Hack, MD/James O. Armitage, MD

10:15 a.m. Utilization of Central Nervous System Prophylaxis in High Grade B-cell LymphomasSonali M. Smith, MDPhilip J. Bierman, MD

10:45 a.m. Utility of X Plus R-CHOP in High Grade B-cell Lymphomas Jason R. Westin, MD, MS, FACPJames O. Armitage, MD

11:15 a.m. Utilization of Radiotherapy in Hodgkin Lymphoma Craig H. Moskowitz, MDAlison J. Moskowitz, MD

11:45 a.m. Utility of Routine Imaging During Continuous Oral TherapiesJonathon B. Cohen, MD, MSJohn P. Leonard, MD

12:15 p.m. Utilization of Maintenance Rituximab in Mantle Cell LymphomaLuhua (Michael) Wang, MDTimothy Fenske, MD, MS

12:45 p.m. Adjourn

1:00-3:00 p.m. Symposium

3:00-4:00 p.m. Ask the Experts: PTCL MODERATOR: Julie M. Vose, MD, MBASteven M. Horwitz, MDKerry J. Savage, MD, MSc, FRCPC

4:00-5:00 p.m. Ask the Experts: MM MODERATOR: Matthew A. Lunning, DO, FACPNina Shah, MDMuhamed Baljevic, MD

7:00-9:00 p.m. Conference Dinner

Friday, Aug 13

7:00 a.m. Breakfast

Best Management StrategiesMODERATOR: Philip J. Bierman, MD

7:30 a.m. Best Management Is Relapsed or Refractory Follicular Lymphoma Jonathon B. Cohen, MD, MS

7:55 a.m. Best Management Is Relapsed or Refractory Marginal Zone Lymphoma Pier Luigi Zinzani, MD, PhD

8:20 a.m. Best Management of Relapsed or Refractory HGBCL Post CAR-T Cell Therapy Grzegorz S. Nowakowski, MD

8:45 a.m. Best Management of TP53 Mutated Mantle Cell Lymphoma Luhua (Michael) Wang, MD

9:10 a.m. Best Management of CD30+ PTCL Post Exposure to Brentuximab Vedotin Kerry J. Savage, MD, MSc, FRCPC

9:35 a.m. Best Management of Hodgkin Lymphoma Post Exposure to Brentuximab Vedotin and Checkpoint InhibitorCraig H. Moskowitz, MD

10:00 a.m. Break

10:15 a.m. Best Management of Relapsed and Refractory CLL/SLL Post BTK and BCL-2 Exposure Alexey V. Danilov, MD, PhD

10:40 a.m. Best Management of Advanced Stage Mycosis Fungoides and Sezary Syndrome Steven M. Horwitz, MD

11:05 a.m. Best Management of Cutaneous B-cell LymphomaR. Gregory Bociek, MD, MSc, FRCP(C)

11:30 a.m. Best Management of HIV Associated High Grade B-cell Lymphomas Avyakta Kallam, MBBS

11:55 a.m. Take Home Messages from 2021 Pan Pacific Lymphoma Conference Matthew A. Lunning, DO, FACP

12:20 p.m. Adjourn

Conference Faculty

Jeremy S. Abramson, MDDirector, Center for Lymphoma, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA

Ranjana H. Advani, MDSaul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

Stephen M. Ansell, MD, PhDChair, Mayo Clinic Lymphoma Group; Professor of Medicine, Mayo Clinic, Rochester, MN

James O. Armitage, MD

Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Muhamed Baljevic, MDAssistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MDProfessor of PET Imaging and NIHR Research Professor, KCL and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom

Nancy L. Bartlett, MDProfessor of Medicine, Koman Chair in Medical Oncology, Washington University School of Medicine, St. Louis, MO

Philip J. Bierman, MDProfessor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

R. Gregory Bociek, MD, MSc, FRCP(C)Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Renier J. Brentjens, MD, PhDDirector, Cellular Therapeutics; Associate Chair, Junior Faculty Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Carla Casulo, MDAssociate Professor, James P. Wilmot Cancer Center, Department of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

Bruce D. Cheson, MD, FACP, FAAAS, FASCOWashington, DC

Jonathon B. Cohen, MD, MSAssociate Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

Alexey V. Danilov, MD, PhDProfessor, Department of Hematology & Hematopoietic Cell Transplantation; Associate Director, Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

Matthew S. Davids, MD, MMScAssociate Director, CLL Center, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA

Andreas Engert, MDProfessor of Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Cologne, Germany

Charles A. Enke, MDProfessor and Chair, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE

Timothy Fenske, MD, MSProfessor, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Richard I. Fisher, MDPresident and CEO, The Robert C. Young MD Chair in Cancer Research, Fox Chase Cancer Center, Philadelphia, PA

Christopher R. Flowers, MD, MS, FASCOProfessor and Chair, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Nathan H. Fowler, MDProfessor; Director, Clinical and Translational Research, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Theresa Franco, MSN, RNVice President, Cancer Center Clinical Operations & Radiology, Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

Jonathan W. Friedberg, MD, MMSc Director, James P. Wilmot Cancer Institute; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

Kai Fu, MD, PhD Professor, Department of Pathology and Microbiology; Co-Director, James O. Armitage Center for Hematological Malignancies Research; Director, International Relations Office, Fred & Pamela Buffett Cancer Center; Director, Asia Pacific Rim Development Program; University of Nebraska Medical Center, Omaha, NE

Tara M. Graff, DO, MSMedical Oncology and Hematology Associates of Iowa, Des Moines, IA

Krishna Gundabolu, MBBS, FACPAssociate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Keely M. Hack, MDGeneral Hematologist and Medical Oncologist, Sanford Cancer Center, Sioux Falls, SD

Steven M. Horwitz, MD Associate Attending, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Brad S. Kahl, MD Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

Avyakta Kallam, MBBSAssistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

David S. Kroll, MDAssociate Vice Chair for Program Development and Innovation, Department of Psychiatry, Brigham Health, Boston, MA

John P. Leonard, MD Richard T. Silver Distinguished Professor of Hematology and Medical Oncology; Associate Dean for Clinical Research, Executive Vice Chairman, Weill Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY

Susanne E. Liewer, PharmD, BCOP, FHOPA Clinical Associate Professor, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE

Peihua (Peggy) Lu, MDMedical Executive President of Lu Daopei Hospital; Director of Lymphoma and Multiple Myeloma Center; Director of Hematology and Oncology Department; Lu Daopei Hospital, Beijing, China

Conference Director

Matthew A. Lunning, DO, FACP

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

David G. Maloney, MD, PhD Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor of Medicine, Division of Oncology, University of Washington, Seattle, WA

David Miklos, MD, PhDAssociate Professor of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA

Alison J. Moskowitz, MDMedical Oncologist; Clinical Director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, New York, NY

Craig H. Moskowitz, MD Physician in Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

Loretta J. Nastoupil, MDLead, Early Phase Drug Development, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Grzegorz S. Nowakowski, MDAssociate Professor, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN

Susan M. O’Brien, MD Professor of Medicine; Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials and Research, University of California/Irvine, Orange, CA

Robbe L. Peetz, MMS, PA-C

Advanced Practice Provider, Manager Cancer Services, Nebraska Medicine, Omaha, NE

Tawny J. Roeder, RN, BSN, BMTCN

Case Manager, Blood and Marrow Transplantation, Division of Oncology and Hematology, Department of Internal Medicine, Nebraska Medicine, Omaha, NE

Kerry J. Savage, MD, MSc, FRCPCProfessor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer, Vancouver, British Columbia, Canada

Nina Shah, MDAssociate Professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Sonali M. Smith, MD Elwood V. Jensen Professor of Medicine; Interim Chief, Section of Hematology/ Oncology; Director, Lymphoma Program, The University of Chicago, Chicago, IL

Christin A. Tiegs Heiden, MDAssistant Professor, Department of Radiology, Mayo Clinic, Rochester, MN

Meg Trewhitt, APN-BC, AOCNPHematology-Oncology Nurse Practitioner, Nebraska Medicine, Omaha, NE

Judith Trotman, MBChB, FRACP, FRCPAClinical Professor, University of Sydney; Head of Department, Haematology, Concord Repatriation General Hospital, Concord, Australia

Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Luhua (Michael) Wang, MDProfessor, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Jason R. Westin, MD, MS, FACPAssociate Professor; Section Chief, Aggressive Lymphoma; Director, Lymphoma Clinical Research Program, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Andrew D. Zelenetz, MD, PhD Medical Director, Quality Informatics; Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Cornell Medicine, New York, NY

Pier Luigi Zinzani, MD, PhDProfessor of Hematology, Institute of Hematology and Medical Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy